Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Intellia Therapeutics (0JBU) Share Price & Analysis

7 Followers

0JBU Stock Chart & Stats

$12.37$0.46(3.86%)
At close: 4:30 PM GMT
$11$12$13Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$11.90 - $12.53
52-Week Range
$7.91 - $19.20
Previous Close
$11.91
Volume
N/A
Average Volume (3M)
21.90K
Market Cap
$1.66B
Enterprise Value
$1.89B
Total Cash (Recent Filing)
$437.76M
Total Debt (Recent Filing)
$73.41M
Price to Earnings (P/E)
―
Beta
0.67
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-0.8
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Lonvo-z Clinical And Regulatory Progress

Lonvo-z has produced strong Phase III efficacy while advancing into FDA Priority Review, materially improving the pathway toward a potential first commercial product. Approval could establish a differentiated one-time HAE treatment and validate Intellia’s in vivo CRISPR platform.

In Vivo Gene-editing Potential

Nex-z demonstrates rapid, deep and durable biological activity from a one-time treatment, supporting the broader potential of Intellia’s gene-editing approach. If later-stage safety and efficacy remain acceptable, this platform could address serious diseases beyond the lead HAE program.

Financial Flexibility And Runway

A substantial cash position and funding runway into at least 2028 give Intellia time to complete key clinical work, pursue regulatory review and prepare for a potential launch. Low balance-sheet leverage also provides flexibility, although future execution remains essential.

Bears Say

Persistent Cash Burn

Intellia remains dependent on external financing because operating activities do not yet generate cash and recent TTM burn has worsened. Continued spending on clinical development and commercialization can consume reserves quickly if approval, partnerships or product revenue are delayed.

Nex-z Liver Safety Risk

The nex-z liver enzyme signal creates a material development and regulatory risk for a major pipeline program. Monitoring, mitigation and regulatory engagement may reduce the issue, but adverse events could complicate dosing, limit eligible patients or delay the program.

Unprofitable Operating Model

Revenue remains modest relative to Intellia’s cost base, leaving the company firmly in an investment phase with deeply negative profitability. This weak earnings profile limits internally funded growth and makes progress toward successful approvals and commercialization critical to future financial sustainability.

Intellia Therapeutics News

0JBU FAQ

What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest share price was $7.91 and its highest was $19.20 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Intellia Therapeutics’s market cap is $1.66B.
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is today.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.001.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of ―. See more information on Intellia Therapeutics dividends here
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -0.80.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 140,126,700 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 0.852%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Hedge funds hold Intellia Therapeutics shares: the largest hedge-fund position in Intellia Therapeutics is 1,774,003,709 shares, and hedge funds increased their holdings by 8.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology